View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 8, 2021updated 11 Jul 2022 2:19pm

Alnylam reports positive data from Phase III hyperoxaluria therapy trial

Lumasiran showed a substantial decline in plasma oxalate in PH1 patients having stage 3b-5 chronic kidney disease.

Alnylam Pharmaceuticals has reported positive six-month data from the Phase III ILLUMINATE-C clinical trial of its therapy, lumasiran, to treat advanced primary hyperoxaluria type 1 (PH1) patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An RNA interference (RNAi) therapy, lumasiran acts on the hydroxyacid oxidase 1 (HAO1), a gene that encodes glycolate oxidase.

The trial enrolled a total of 21 subjects. Of these, six requiring no dialysis were categorised into Cohort A while the other 15 subjects needing hemodialysis were in Cohort B.

The trial’s primary efficacy goal is the change in plasma oxalate (POx) in Cohort A and predialysis POx in Cohort B from baseline to six months, with an average across three to six months.

Primary analysis findings showed that the therapy provided a substantial decline in plasma oxalate (POx) in PH1 patients with stage 3b-5 chronic kidney disease, irrespective of their dialysis status.

From baseline to month six, lumasiran respectively offered 33% and 42% mean reductions in POx and predialysis POx in Cohorts A and B.

The decline in POx was noted in month one and continued until the completion of the primary assessment period of six months.

Lumasiran had a satisfactory safety profile in the trial with mild and temporary injection site reactions being the most common adverse event observed in 24% of the subjects.

Alnylam Lumasiran programme general manager Jeroen Valkenburg said: “PH1 patients progressing to or being diagnosed with end-stage kidney disease often have substantial elevations in plasma oxalate despite intensive hemodialysis.

“The ILLUMINATE-C results underscore the potential of lumasiran to achieve meaningful reductions in plasma oxalate in patients with impaired kidney function, including those on hemodialysis, who are at risk of systemic oxalosis and multiorgan damage.”

The company intends to submit the data to the US and European regulatory agencies this year to obtain a label extension for lumasiran.

Lumasiran is currently approved by the US Food and Drug Administration to reduce urinary oxalate levels in adult and paediatric PH1 patients.

In August this year, Alnylam concluded subject enrolment for the Phase III HELIOS-B trial of vutrisiran for the treatment of cardiomyopathy in patients with transthyretin-mediated amyloidosis.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena